Video content is prompted by the following: PARP Inhibitors in Ovarian Cancer Treatment Key Themes: Biomarker-directed PARP inhibitor use in frontline treatment Current FDA approvals and indications Overall survival concerns in platinum-sensitive settings Notable Insights: Current frontline approvals: Olaparib monotherapy […]
The Use of PARP Inhibitors in Ovarian Cancer Read More »
Video content is prompted by the following: Early Introduction of Antibody-Drug Conjugates Key Themes: Clinical trials evaluating antibody-drug conjugates (ADCs) in earlier treatment settings Integration of biomarkers in treatment decision-making Balancing efficacy against toxicity profiles Notable Insights: ADCs are advancing
Earlier Introduction of Antibody-Drug Conjugates Read More »
Video content is prompted by the following: Sequencing Antibody-Drug Conjugates in Platinum-Resistant Ovarian Cancer Panelist Introduction AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel
Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer Read More »
Video content is prompted by the following: Novel Targeted Therapies in the Treatment Landscape Key Themes: Emergence of antibody-drug conjugates (ADCs) targeting various receptors Movement of ADCs into earlier treatment settings Biomarker-directed therapy approach Notable Insights: Multiple ADCs are in
The Role of Novel Targeted Therapies Read More »
